Structure Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 93
- Market Cap
- -
- Introduction
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.
Synfini and Multispan Partner to Accelerate GPCR Drug Discovery Using AI and Automation
Synfini, Inc. and Multispan have formed a strategic collaboration to co-discover and develop drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), combining AI-driven chemistry with specialized GPCR biology expertise.
Maxion Therapeutics Secures $72M Series A to Advance Novel KnotBody Platform for Ion Channel Diseases
Maxion Therapeutics has raised $72 million in an oversubscribed Series A financing led by General Catalyst, with participation from British Patient Capital, Solasta Ventures, Eli Lilly and existing investors.
Nxera Pharma Partners with Holling Bio-Pharma to Launch Daridorexant for Insomnia in Taiwan
Nxera Pharma has established a strategic partnership with Holling Bio-Pharma, Taiwan's largest pharmaceutical distributor, to commercialize daridorexant for insomnia treatment in the Taiwanese market.
Verily and Sosei Heptares Achieve Early Success in AI-Powered GPCR Drug Discovery for Autoimmune Diseases
Verily's Immune Profiler platform has successfully identified novel GPCR targets for autoimmune diseases within six months of launching collaboration with Sosei Heptares.
Septerna Raises $288M in Upsized IPO to Advance Novel GPCR-Targeting Drug Pipeline
Septerna successfully completed an upsized IPO raising $288 million, selling 16 million shares at $18 each, demonstrating strong investor confidence in clinical-stage biotech companies.